Laurus Labs Limited

rs,

April 30, 2026 To To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 The Listing Department National Stock Exchange of India Ltd., Ex

25%

ator in Indian Healthcare space ^ [₹ Crore] # Amongst few companies in India which has earned >25% Revenue CAGR and >30% Profits CAGR Laurus Labs: 11.6x BSE 500 index: 3.3x Pharma index India:

30%

re space ^ [₹ Crore] # Amongst few companies in India which has earned >25% Revenue CAGR and >30% Profits CAGR Laurus Labs: 11.6x BSE 500 index: 3.3x Pharma index India: BSE Health: 3.0x / Nif

11.6x

t few companies in India which has earned >25% Revenue CAGR and >30% Profits CAGR Laurus Labs: 11.6x BSE 500 index: 3.3x Pharma index India: BSE Health: 3.0x / Nifty Pharma: 2.1x MSCI India SmallC

3.3x

dia which has earned >25% Revenue CAGR and >30% Profits CAGR Laurus Labs: 11.6x BSE 500 index: 3.3x Pharma index India: BSE Health: 3.0x / Nifty Pharma: 2.1x MSCI India SmallCap: 3.0x Total Marke

3.0x

R and >30% Profits CAGR Laurus Labs: 11.6x BSE 500 index: 3.3x Pharma index India: BSE Health: 3.0x / Nifty Pharma: 2.1x MSCI India SmallCap: 3.0x Total Market cap >30% CAGR since 2016 till now

2.1x

GR Laurus Labs: 11.6x BSE 500 index: 3.3x Pharma index India: BSE Health: 3.0x / Nifty Pharma: 2.1x MSCI India SmallCap: 3.0x Total Market cap >30% CAGR since 2016 till now Total dividend payout

₹631 crore

CI India SmallCap: 3.0x Total Market cap >30% CAGR since 2016 till now Total dividend payout of ₹631 crore till now From Single API product supplier to Global Pharma company Case study for Scale and Execu

₹1000

# Shareholder base 3 56,724 ^ 15 3,00,789 # Profit year, ^ since Laurus IPO (Dec 2016) and ₹1000 Cr + Revenues category, based on Price as on 24 April 2026 © 2026 Laurus Labs Ltd. FY26 Results

74x

Price as on 24 April 2026 © 2026 Laurus Labs Ltd. FY26 Results Presentation 30/04/2026 4 32x74x - 2,000 4,000 6,000 8,000FY10FY26RevenuesProfits FY 2026 – Accelerated performance backed by Leadin

₹6,813

2026 – Accelerated performance backed by Leading commercial offering Full Year 2026 in numbers ₹6,813 Cr Revenues +23% 60.4% Gross margin +5% 8,200 KL Reactor volume 8,126 Employees +15% 4Q 20

23%

rformance backed by Leading commercial offering Full Year 2026 in numbers ₹6,813 Cr Revenues +23% 60.4% Gross margin +5% 8,200 KL Reactor volume 8,126 Employees +15% 4Q 2026 ₹1,812 Cr Re